CA-ULTRAVIOLET-DEVICES
12.10.2020 08:02:14 CEST | Business Wire | Press release
Ultraviolet Devices, Inc. (UVDI), a global leader in UV-C surface disinfecting and indoor air quality products, today announced its first Italian hospital studies demonstrating the advanced effectiveness of the UVDI-360 Room Sanitizer will be presented at the 16th World Congress on Public Health 2020, taking place October 12 – 16, 2020. The novel research, conducted by Dr. Gabriele Messina, Associate Professor of Public Health, University of Siena, at the Rugani Hospital Monteriggioni in Siena, demonstrates the UVDI-360’s ability to inactivate pathogens in the hospital environment as part of varied cleaning protocols, in multiple high-risk locations and at different disinfecting cycle times.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005076/en/
Presentations from Dr. Messina and his Team at the University of Siena include:
(1) one poster sharing preliminary data of a cross-sectional study measuring overall pathogen reduction on high-touch surfaces in hospital rooms pre-and-post use of the UVDI-360 Room Sanitizer as a supplement to terminal cleaning. Preliminary findings conclude 83% of sites sampled had 0 CFU following the use of the UVDI-360 Room Sanitizer.
(2) a second poster sharing preliminary data of a cross-sectional study demonstrating overall pathogen reduction in operating rooms in six minutes with the UVDI-360 Room Sanitizer used in multiple protocols: with no manual cleaning, manual cleaning in-between operating room use and as a supplement to manual terminal cleaning.
(3) an oral presentation sharing research demonstrating 3-and-4-log reductions of Candida auris at 2.44 meters using the UVDI-360 Room Sanitizer.
(4) a third poster illustrating a simulation model of microbe distribution on surfaces to inform future UV-C testing.
Title:
Six ultraviolet minutes for cleaner operating theatres
Track:
Health Technology Assessment
Abstract: #
DJ-15
Title: Analytical approach for a better control of environmental contamination
Track:
Hospital hygiene (including AMR), healthcare-associated infections (HAI)
Abstract:
#DN-18
Title:
A simulation model of microbe overlapping for the correct estimation of UV-C device log-reduction
Track:
Healthcare Technology Assessment
Abstract: #
DJ-14
Oral Presentation:
Tuning a UV-C device to challenge new threats in the sanitization setting of healthcare facilities
Date and Time:
October 13th
, 12:15-13:15
Poster abstracts are accessible via the World Congress website, https://wcph2020.com/ . The poster presentations may be accessed through UVDI’s website following their presentation.
About UVDI
UVDI's Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. Founded in 1949 by Louis Veloz, UVDI designs and makes next-generation germicidal Ultraviolet light solutions in California applying over 70 years and three generations of family craftsmanship and care. The UVDI-360 Room Sanitizer is now used globally in over 25 countries in the world’s leading hospitals, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate the highest-risk pathogens. UVDI is proud to be a certified Minority Business Enterprise (MBE).
View source version on businesswire.com: https://www.businesswire.com/news/home/20201011005076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
